Ligand(LGND) - 2023 Q4 - Earnings Call Transcript

The team is extremely excited about the potential for this program. We're in process of building a new standalone company called Pathios Therapeutics that will commercialize ZELSUVMI. Company creation effort is very similar to our prior efforts related to Viking Therapeutics and Primrose Bio. ZELSUVMI operated fully independent of Ligand, but we expect to own a significant equity stake in the business at inception. While we are having discussions with potential strategic licensing partners, we're also makin ...